TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER).
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
| Metabolism | Metabolized via amino acid oxidation and gluconeogenesis in the liver and kidneys. Dextrose undergoes glycolysis and oxidative phosphorylation. Electrolytes are not metabolized but excreted or retained as needed. |
| Excretion | Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible. |
| Half-life | Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary. |
| Protein binding | None for components. Amino acids: minimal (<10%). |
| Volume of Distribution | Not applicable as a mixture; individual components distribute into total body water (0.6 L/kg) or extracellular fluid (0.2 L/kg). |
| Bioavailability | Intravenous: 100% (only route). |
| Onset of Action | Intravenous: immediate (within minutes) for caloric and electrolyte effects. |
| Duration of Action | Intravenous: caloric effect persists while infused; rapid decline post-infusion. Clinical effect: continuous during administration. |
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 mL/min, adjusted to meet metabolic requirements.
| Dosage form | INJECTABLE |
| Renal impairment | In renal impairment (GFR <30 mL/min): restrict fluid and electrolytes; use specialized amino acid formulations (e.g., essential amino acid solutions). Dextrose content may cause hyperglycemia; monitor glucose. Reduce volume and electrolytes as needed. For non-dialysis patients, avoid unless specific benefits outweigh risks. |
| Liver impairment | In hepatic impairment (Child-Pugh class B or C): monitor for encephalopathy; amino acid load may precipitate hepatic encephalopathy. Use lower protein intake (0.6-0.8 g/kg/day) or branched-chain amino acid enriched solutions. Dextrose may exacerbate hyperglycemia; adjust insulin as needed. |
| Pediatric use | Weight-based: neonates 1-3 g/kg/day amino acids, up to 15 g/kg/day dextrose, titrated. Infants and children: 1-2 g/kg/day amino acids, 10-20% dextrose at 1-2 mL/kg/hour. Adjust electrolytes per serum levels. Use age-specific formulations; monitor growth and metabolic parameters. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER).
| Breastfeeding | It is not known whether components of this solution are excreted in human milk. No M/P ratio available. Caution should be exercised when administered to a breastfeeding woman. The high dextrose content may affect maternal glucose levels, indirectly influencing milk composition. Consider the benefits of breastfeeding and the importance of the drug to the mother. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if clearly needed. Potential fetal risks include metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) associated with maternal administration of dextrose and electrolytes, which may affect fetal homeostasis. However, no specific teratogenic effects have been documented. |
■ FDA Black Box Warning
Not for intravenous injection as a sole source of nutrition. Contains aluminum that may be toxic. Use with caution in renal impairment due to aluminum accumulation. Do not administer unless solution is clear and container undamaged.
| Serious Effects |
["Anuria or severe renal impairment without appropriate monitoring","Inborn errors of amino acid metabolism (e.g., phenylketonuria)","Severe electrolyte disorders before correction","Hyperglycemia uncontrolled by insulin","Hypersensitivity to any component"]
| Precautions | ["Risk of hyperglycemia, especially in diabetic patients","Electrolyte imbalances (hyperkalemia, hypophosphatemia, etc.)","Volume overload in patients with heart failure or renal disease","Aluminum toxicity with prolonged use, especially in renal impairment","Thrombophlebitis and infection at infusion site","Refeeding syndrome in malnourished patients"] |
Loading safety data…
| Elderly: start at lower volume (0.5-1 L/day) due to reduced renal function and fluid reserve. Monitor glucose and electrolytes closely; dextrose load may require insulin. Amino acid dosing per protein requirements (1-1.2 g/kg/day if no renal impairment). Adjust for comorbidities. |
| Fetal Monitoring | Monitor maternal blood glucose, serum electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate), serum osmolarity, acid-base balance, and fluid status. Assess for signs of hyperglycemia, electrolyte disturbances, and fluid overload. Fetal monitoring may be indicated in cases of maternal metabolic instability. |
| Fertility Effects | Effects on fertility have not been studied. No specific data available regarding impact on male or female fertility. The underlying condition requiring parenteral nutrition may influence fertility. |